Safety and Clinical Efficiency of Using Combined Preparation of Metformin Extended-Release and Glimepiride
The article explains the early use of a combination of glucose-lowering drugs that act on different stages of pathogenesis of diabetes mellitus (DM) type 2.
The aim of the study was to evaluate changes in the indicator of glycosylated hemoglobin (HbA1c) after the observation period compared with baseline, as well as the determination of additional parameters of efficacy, safety and tolerability of Duglimax manufactured by Kusum Pharm (Ukraine) in the treatment of patients with DM type 2.
Materials and Methods. We observed 35 patients with DM type 2, which were divided into two groups. The patients of the first group (16 patients), HbA1c levels did not exceed 8.0 %. The second group is formed of 19 patients with DM type 2 and level of HbA1c from 8.0 to 10.0 %.
The Results of the Study. Normalization of blood glucose in patients receiving Duglimax resulted in a decrease in HbA1c in patients both of first and second group. Weight loss contributed to reduced waist circumference (WC). Both groups of patients showed a trend to reduction of low-density lipoprotein (LDL) cholesterol. The results of the clinical studies indicate a lack of development of hypoglycaemia in patients in patients receiving Duglimax during the observation period.
Conclusions. Administration of a combined anti-diabetic therapy with Duglimax for 24 weeks results in a significant reduction in HbA1c and the achievement of the targets of carbohydrate metabolism in patients with DM type 2. On the background of normalization of carbohydrate metabolism using combination therapy helps moderate decrease in body weight and WC value, to reduce serum LDL. Good tolerability and high degree of safety of Duglimax throughout the observation period were noted.
Full Text:PDF (Українська)
Дедов И.И. Сахарный диабет — опаснейший вызов мировому сообществу / И.И. Дедов // Вестник РАМН. — 2012. — № 1. — С. 7-13.
IDF Diabetes Atlas Update 2012. — http://www.idf.org/diabetesatlas/5e/Update 2012.
Wild S., Roglic G., Green A. et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 // Diabetes Care. — 2004. — Vol. 27. — P. 1047-1053.
Juurlink D.N. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population / D.N. Juurlink, T. Gomes, B.R. Shah, M.M. Mamdani // Diabet. Med. — 2012. — Vol. 29, № 12. — P. 1524-1528.
Wilmot E.G. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis / E.G. Wilmot, C.L. Edwardson, F.A. Achana [et al.] // Diabetologia. — 2012. — Vol. 55, № 11. — P. 2895-2905.
Stratton I.M., Adler A.L., Neil H.A. et al. Association of glycaemia macrovascular and microvascular complications of type 2 (UKPDS 35): prospective observational study // BMJ. — 2000. — Vol. 321. — P. 405-412.
Shernthaner G. et al. Fixed-dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care // Diabetes Med. — 2010. — Vol. 27. — P. 739-743.
McEwan P., Evans M., Kan H., Bergenheim K. Understanding the interrelationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model // Obes. Metab. — 2010. — Vol. 12 — P. 431-406.
Loubani M., Fowler A., Standen N.B., Galinanes M. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. // Eur. J. Pharmacol. — 2005. — Vol. 515 — P. 142-149.
Icks A. Time-dependent impact of diabetes on mortality in patients with stroke: survival up to 5 years in a health insurance population cohort in Germany / A. Icks, H. Claessen, S. Morbach [et al.] // Diabetes Care. — 2012. — Vol. 35, № 9. — P. 1868-1875.
Copyright (c) 2020 V.I. Pankiv
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2020